Spearhead Capital Advisors, LLC Ultragenyx Pharmaceutical Inc. Transaction History

Spearhead Capital Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$45.8 - $85.4 $2,656 - $4,953	-58 Reduced 1.35%	4,232 $252,000
Q1 2022 Apr 28, 2022	BUY	$62.2 - $84.4 $23,698 - $32,156	381 Added 9.75%	4,290 $312,000
Q4 2021 Jan 25, 2022	BUY	$73.71 - $87.86 $28,599 - $34,089	388 Added 11.02%	3,909 $329,000
Q3 2021 Oct 27, 2021	BUY	$77.92 - $102.4 $15,817 - $20,787	203 Added 6.12%	3,521 $318,000
Q2 2021 Aug 10, 2021	BUY	$92.19 - $115.71 $50,704 - $63,640	550 Added 19.87%	3,318 $316,000
Q1 2021 Apr 28, 2021	BUY	$106.9 - $167.73 $295,899 - $464,276	2,768 New	2,768 $315,000

325

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.13B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Spearhead Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Spearhead Capital Advisors, LLC with notifications on news.